Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 2,738 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastrointestinal Carcinoma Clear all

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer, Stage III Esophageal Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions: saracatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Dalton, Georgia

Conditions: Rectal Cancer
Interventions: Sorafenib, 5-Fluorouracil (5-FU), Radiation; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions: Durvalumab, Laboratory Biomarker Analysis, Tremelimumab; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary
Interventions: PSMA/PRAME; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more

Conditions: Neoplasms
Interventions: ADH300004; Drug
Lead sponsor: Adherex Technologies, Inc.; Industry
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions: A2B694, A2B543, xT CDx with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions: MCLA-129, Osimertinib, Chemotherapy; Drug
Lead sponsor: Merus B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more

Conditions: Colorectal Cancer
Interventions: Arsenic trioxide, Fluorouracil, Leucovorin calcium, Plasma levels of elemental arsenic, Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis, Tumor Biopsy (Fine-Needle Aspiration); Drug · Other · Genetic + 1 more
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
Interventions: allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa, recombinant interferon gamma, sargramostim, cyclophosphamide; Biological · Drug
Lead sponsor: St. Vincent Medical Center - Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
Interventions: Amifostine, Carboplatin, Paclitaxel, radiation; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 9
States / cities: Sanford, Maine • Boston, Massachusetts • Concord, Massachusetts + 4 more

Conditions: HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
Interventions: E7 TCR-T cells, Aldesleukin; Biological · Drug
Lead sponsor: Christian Hinrichs; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: New Brunswick, New Jersey

Conditions: Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma, Gastric Cancer, Pancreatic Cancer, Urothelial Cancer
Interventions: GEN1029 (HexaBody®-DR5/DR5); Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: New Haven, Connecticut • Houston, Texas

Conditions: Hepatocellular Carcinoma
Interventions: Axitinib (AG-013736), Best Supportive Care, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 13
States / cities: Berkeley, California • La Jolla, California • Orange, California + 7 more

Conditions: Colorectal Cancer, Head and Neck Cancer
Interventions: Nilotinib + Cetuximab; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Colorectal Cancer
Interventions: Irinotecan, CyberKnife; Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Hepatocellular Carcinoma
Interventions: Plasma collection; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 35
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more

Conditions: Hepatocellular Carcinoma
Interventions: TheraSphere; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colon Adenocarcinoma, Colorectal Carcinoma, Rectal Adenocarcinoma
Interventions: Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 818 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2030
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas • League City, Texas + 1 more

Conditions: Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
Interventions: phenoxodiol, carboplatin, placebo; Drug
Lead sponsor: MEI Pharma, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 37
States / cities: Tuscon, Arizona • Glendale, California • Los Angeles, California + 32 more

Conditions: Carcinoma, Hepatocellular
Interventions: Sorafenib (Nexavar, BAY43-9006); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Advanced Solid Tumors
Interventions: OSI-906; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hepatocellular Carcinoma
Interventions: Tivantinib, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 17 more

Conditions: Extrahepatic Bile Duct Cancer, Liver Cancer
Interventions: fluorouracil, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Randomized Amifostine For SCCHN

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma

Young-Onset Colorectal Cancer

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Study of Continuous OSI-906 Dosing

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy

Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer